Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03581942 · ClinicalTrials.gov registry record · Phase 1
Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL)
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT03581942: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03581942 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 18 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03581942, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety of combined use of the study drugs, copanlisib and ibrutinib, in people with PCNSL.
Interventions
- DRUG Ibrutinib
- DRUG Copanlisib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2018-08-23 |
| Est. Completion | 2026-02-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03581942
The ClinicalTrials.gov registry entry for NCT03581942 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ibrutinib is the first listed.
NCT03581942 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03581942 about?
NCT03581942 is a clinical study titled "Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL)". The purpose of this study is to test the safety of combined use of the study drugs, copanlisib and ibrutinib, in people with PCNSL.
What is the current status of trial NCT03581942?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2018-08-23. Estimated completion is 2026-02-05.
What interventions are being tested in trial NCT03581942?
The interventions under investigation include: Ibrutinib (DRUG), Copanlisib (DRUG).
Who is sponsoring clinical trial NCT03581942?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.